INVERSAGO-PHARMA-INC.
29.9.2020 14:02:30 CEST | Business Wire | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH).
The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Recruitment is ongoing and will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose levels of INV-101.
“With the launch of this first-in-human trial, Inversago is now a clinical-stage company, and confirms its lead in the comeback of small molecule peripheral CB1 blockers”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma.
“Dosing of our first patient with INV-101 represents an important milestone to accomplish the Company’s vision: offering a potentially meaningful therapeutic option to underserved patient populations, like in PWS and NASH" said Carlo Incerti, M.D., Chairman of the Board of Inversago. "This study is the first step in the clinical development of our peripherally-acting CB1 blockers, and we expect it to provide important information about its safety and pharmacokinetics profile", concluded Dr. Incerti.
The Company’s second program, INV-202, is presently in IND-enabling preclinical studies, while other programs are in earlier stages of development. With its current pipeline, Inversago is well positioned to fully exploit peripheral CB1 blockade for a wide range of underserved metabolic indications with differentiated products.
About INV-101
INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and NASH. It is specifically designed to interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com .
Picture of our CEO and company logotype available for download at: inversago.com/en/media/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005408/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group’s AI Health App AQ Reaches 150 Million Users as It Expands AI-powered Day-to-day Health Use Cases10.9.2026 14:47:00 CEST | Press release
At the 2026 INCLUSION · Conference on the Bund in Shanghai, Zhang Junjie, Vice President of Ant Group and Head of the Health Business, announced that Ant Group’s flagship AI health app AQ has reached 150 million users, handling nearly 20 million health inquiries per day. The new milestone also means AQ has grown its user base by 50% in just 8 months, since it announced 100 million users in February 2026, reflecting strong demand in China’s AI health space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910921103/en/ Ant Group’s AI health app AQ provides personalized health advice based on more than 10 health indicators. Health has become an increasingly important priority among Chinese consumers. According to Accenture’s China Consumer Insights report published in November 2025, the share of Chinese consumers who considered health a priority increased from 78% in 2021 to 87% in 2025, making it the top priority among the a
AULUMU Introduces A18 Series for iPhone 18 With Aramid Fibre, Hybrid Protection and Distinctive Finishes10.9.2026 14:43:00 CEST | Press release
Technology accessories brand aulumu has introduced the A18 Series for iPhone 18, a new collection of smartphone cases designed around lightweight protection, material innovation and distinctive visual finishes. The range includes the A18 Armor Shockproof Aramid Fiber Case, two ultra-slim aramid fibre models, the Ghost Lumen Transparent Case, and the Particle Vegan Leather Case. At the centre of the collection, the A18 Armor combines 1500D aramid fibre and thermoplastic polyurethane (TPU) in a one-piece construction. The hybrid structure pairs the light weight and woven texture of aramid fibre with the flexibility and cushioning properties of TPU. A full-wrap design covers the phone’s edges, while reinforced corners are intended to help distribute impact from everyday drops and bumps. The case is designed to provide drop protection from heights of up to 2 metres, with a 1.36 mm raised screen edge and a 1.3 mm raised camera frame providing additional protection around key areas. The A18
BGC Group Announces its First-Ever Fully AI Brokered Institutional Trade in Listed Equity Derivatives10.9.2026 14:30:00 CEST | Press release
Fully autonomous transaction between two institutional accounts marks milestone in AI-powered trading BGC Group Inc. (Nasdaq: BGC) (“BGC”), a leading global brokerage and financial technology company servicing financial markets, today announced it has launched Fenics AI, and that its subsidiary, Aurel BGC, has completed its first-ever fully AI brokered institutional trade in listed equity derivatives, using autonomous AI-powered systems to manage the trading workflow from price discovery through to execution. Fenics AI, BGC’s new proprietary AI trading technology, arranged this landmark transaction on September 3, 2026, in Eurex listed Swiss SMI options between two institutional accounts, including Hudson Bay Capital. This successful first AI trade follows rigorous development and testing to ensure compatibility with applicable market conventions, rules and governance. Fenics AI is expected to be made available to BGC’s clients during the fourth quarter 2026 to deliver significant effi
Coulson Aviation Defines the Next Chapter of Innovation With EmberWorks10.9.2026 14:03:00 CEST | Press release
Dedicated division connects operational experience with the development and testing of new wildfire and emergency-response technologies. Coulson Aviation is moving forward with EmberWorks, its dedicated innovation division created to turn real-world operational challenges into new capabilities for aerial firefighting, aviation, and emergency response. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910644135/en/ Comparison imagery demonstrates how ORBIT uses airborne thermal sensing and automated processing to identify wildfire activity and generate geolocated fire intelligence. First introduced at the Aerial Fire Fighting Global Conference in Rome earlier this year, EmberWorks formalizes an approach to innovation that has existed throughout Coulson’s history. From aircraft modification and mission-system development to programs such as C-130 airtanker, Boeing 737 Fireliner, and CH-47 Chinook helicopter, Coulson has long d
Radisys Launches V.AI Ecosystem to Accelerate Telecom AI Service Innovation10.9.2026 14:00:00 CEST | Press release
Combines turnkey applications, developer tools and leading voice and speech AI technologies from industry-leading partners, helping operators launch and monetize intelligent communications services faster Radisys® Corporation, a global leader in open telecom solutions, today announced the launch of its V.AI ecosystem, bringing together applications, development tools and leading voice and speech AI technologies to help telecom operators create, deploy and monetize AI-powered communication services for consumers and business subscribers. The V.AI ecosystem, which has evolved since the launch of the Radisys Engage Digital Platform (EDP) at MWC Barcelona in 2022, draws on two decades of Radisys leadership in real-time media processing and a global footprint across live operator networks. Seamlessly integrated with EDP, the ecosystem gives operators multiple paths to market. Operators can deploy turnkey applications, customize services for specific markets and customer segments, or create
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom